Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14787210.2020.1800453 http://scihub22266oqcxt.onion/10.1080/14787210.2020.1800453 32693650!7441800!32693650     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32693650&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Anti+Infect+Ther 2021 ; 19 (1): 93-100 Nephropedia Template TP {{tp|p=32693650|t=2021. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study |pdf=|usr=}}{{32693650}} gab.com Text Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study JO: Expert Rev Anti Infect Ther http://www.kidney.de/pget.php?&tw=1&pmid=32693650 #FOAvip BACKGROUND: Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. METHODS: This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. RESULTS: Twenty-eight patients were included (19 male), with a mean age of 61.7 +/- 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 +/- 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p </= 0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination. CONCLUSIONS: Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients. Twit Text FOAVip Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study ????Expert Rev Anti Infect Ther http://www.kidney.de/pget.php?&tw=1&pmid=32693650 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32693650 #FOAvip English Wikipedia <ref>{{Cite pmid|32693650}}</ref> Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study #MMPMID32693650 Tomasiewicz K; Piekarska A; Stempkowska-Rejek J; Serafinska S; Gawkowska A; Parczewski M; Niscigorska-Olsen J; Lapinski TW; Zarebska-Michaluk D; Kowalska JD; Horban A; Flisiak R Expert Rev Anti Infect Ther 2021[Jan]; 19 (1): 93-100 PMID32693650show ga BACKGROUND: Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce. METHODS: This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. RESULTS: Twenty-eight patients were included (19 male), with a mean age of 61.7 +/- 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 +/- 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use[MESH] |COVID-19/diagnostic imaging/immunology[MESH] |Female[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |Male[MESH] |Middle Aged[MESH]Tocilizumab for patients with severe COVID-19: a retrospective, multi-(epmc).pdf DeepDyve Pubget Overpricing